In this time of dire need, Sepragen team is doing its part to solve the problem of COVID-19. We are providing equipment on an expedited basis to a company developing a vaccine for COVID- 19.
About Us
Sepragen Corporation, based in Union City, California, provides break-through products and processes to the biotechnology and nutraceutical industries for their process development and manufacturing needs. Our products enable our customers several fold higher productivity in a smaller footprint, ease of use and rapid, predictable scale up of processes from the laboratory to production. This results in lower capital outlay, lower cost of goods and rapid time to market. All products are designed and manufactured to the highest standards of quality and with the standards of traceability and cGMP compliance. Sepragen provides all the necessary documentation support and support services related to validation, IQ/OQ and follow on preventative maintenance.

In the biotechnology industry our products are used by industry leaders on four continents and are today used in making 24 FDA approved drugs. Sepragen’s growing menu of products includes both downstream and upstream products. All unique and backed by 16 patents these products include chromatography columns and accessories, column packing systems, chromatography systems, chromatography resins and bioreactors. As with its product portfolio Sepragen’s geographical footprint has also expanded with the addition of its latest manufacturing operation in India and a growing base of distributors.

Outside of biotechnology, Sepragen has developed and patented processes to isolate proteins from dairy whey, remove bitterness from citrus juices, isoflavones from soy and trace contaminants such as heavy metals and organics from process and ground water. Several of these processes have been licensed to third parties.

Sepragen Corporation – company video

Values
We bring our unbridled innovative spirit in service of you, the customer. We will reach for products and solutions that will help you develop and manufacture life saving drugs rapidly and cost effective within the framework of compliance. We operate with a spirit of fairness, integrity, teamwork and mutual respect. We deliver what we promise.
Quality
As a leading manufacturer of liquid chromatography products, Sepragen is committed to total quality management. Our entire staff is pledged to provide superior products and services to our customers. To assure the uncompromising quality our customers require, Sepragen applies a comprehensive program of standard operating procedures to all our products. We are committed to meeting various international standards as applicable such as: ISO 9001, 2000, CE, FDA Compliance, 21 CFR Pt.11, USP Grade VI, ASME, and GAMP4, amongst others.
Company timeline
History of innovation
1985
Sepragen founded
1987
Radial Flow Columns invented
1990
Production Scale Radial Flow Columns developed and installed for Manufacturing (IVIG at Baxter, now Takeda)
1992
Quantasep Lab-scale Chromatography system developed
1994
Production Scale Radial Flow Columns installed at Octapharma for EMEA Approved manufacture of Factor VIII
1994
Pilot Scale Chromatography system developed
1995
Sepragen develops the dual flow-path Quantasep 1000LX model
1996
Sepragen supplies Amgen with Radial Flow Columns for GSF production
1997
Sepragen develops Commercial Process for isolating Lactoferrin from Whey or skim milk
1998
Sepradebitt Process developed for removing bitterness from Grapefruit Juice
2002
Sepragen develops process technology for isolating Alpha Lactalbumin from whey
2002
Sepragen acquires technology for monolith Cellulose ion exchange chromatography
2004
Sepragen signs distribution agreement for Quantasep lab scale Chromatography system with Pall Corporation
2006
Sepragen develops and installs 600LPH Chromatography systems
2008
Explosion Proof Quantasep 2400 LPH SS Production Scale Systems delivered to GSK for FDA Phase 3 Clinical Production
2009
Sepragen acquires technology for wicking matrix bioreactor for cell expansion and perfusion cell culture
2011
Sepragen acquires technology for wicking matrix bioreactor for cell expansion and perfusion cell culture
2013
Sepragen Develops 600 LPH Buffer Dilution System
2014
Sepragen develops and delivers 1000 LPH Chromatography System combing Chromatography with Buffer Dilution for Commercial Mab production
2015
Sepragen develops 0-200 LPH Chromatography System with Single Use flow-path for FDA approved Viral Vector Production
2017
Sepragen supplies Radial Flow Columns for 5 to/ yr Lactoferrin Production Plant
2018
Sepragen Supplies Radial Flow Columns for 15 ton/ yr Lactoferrin plant
2018
Sepragen supplies Radial Flow Columns for 5 to/ yr Lactoferrin Production Plant
2018
Sepragen Develops Continuous Capture Chromatography System integrated with buffer blending capability for 2000L Perfusion for major Biopharma
2019
Sepragen Develops and delivers to major biopharma a Continuous Flow-through Chromatography Skid with integrated unit operations for IEX, HIC and NF combined with Buffer Blending for 2000L scale production
2020
Sepragen develops and delivers 5 Chromatography skids up to 1000 LPH Single-use Chromatography systems with In-line buffer dilution capabilities for vaccine production
2021
Sepragen Delivers to Serum Institute of India multiple 7500LPH Chromatography systems combined with Buffer Blending for manufacture of 200M doses/ mo. of Covid-19 vaccine
2021
Sepragen Delivers 60 lpm Chromatography skid with In-line Buffer Dilution Capability for use in mRNA Covid-19 vaccine production

Sepragen delivers state-of-the-art manufacturing equipment for the production of COVID-19 vaccine
Our clients
Meet the team
Management Team
Vinit Saxena
CEO and Chief Technology Officer
Mr. Vinit Saxena is the founder and CEO of Sepragen Corporation, a company specializing in providing innovative and award-winning bio-processing equipment and consumables for the production and purification of biological drugs, high-end nutritional and dairy ingredients and vaccines. Sepragen's patented technologies are used globally in producing 30 FDA approved drugs including 100s of millions of doses of two approved and well known Covid-19 vaccines. Sepragen’s customers are on 4 continents and include bio-pharma industry leaders such as Abbvie, Amgen, GSK, Octapharma, Novartis, Sanofi, Takeda, Serum Institute and Biocon as well several leading nutritional companies such as Arla, Bega, Carbery and Mead Johnson. Sepragen’s products enable high throughput purifications and rapid scale-up at lower costs. Mr. Saxena’s industry experience spans over thirty-five (35) years including senior roles in marketing and manufacturing at leading life science suppliers and CMOs. Mr. Saxena is a graduate of IIT Kanpur, India and has an MS in Chemical Engineering from Syracuse University and an MBA from U.C. Berkeley. He has authored over 15 patents and several publications in trade press and peer reviewed journals. He has been a featured presenter and chair at several industry conferences and panels. He is on the Scientific Advisory Board of The Keck Graduate Institute, Claremont, CA and served as adjunct faculty advisor to doctoral students. He is also the winner of several SBIR grants and the prestigious IR 100 award.
Henry Edmunds
acting CFO
Dr. Edmunds is currently acting as Chief Financial Officer of Sepragen. He also serves as President of Biopheresis. Previously, he served as Vice President and Chief Financial Officer of Prometheus, a pharmaceutical company. He also served as Vice President of Corporate Development and Chief Financial Officer of SangStat Medical Corporation, and as Director of Business development at Genencor, Inc. Dr. Edmunds received his Ph.D. in Biotechnology from the University of California, Berkeley and his M.B.A. from the Stanford School of Business.
Renu Chabra
VP Manufacturing and Engineering
Renu Chabra is the COO of Sepragen. An engineer by training, she has 30+ years of industry experience in senior technical and executive roles in life science instrumentation, medical devices and A.I. at companies such as Varian, Quintus, Kinetech and Scanis. Renu has been at Sepragen for over 25 years and over that time has been the architect of developing Sepragen’s array of Chromatography portfolio of instruments including single-use and buffer blending systems and the innovative electronics and software that drives them. She is also the steward of Sepragen developing a company culture which is driven by people “keeping their word” and developing an extraordinarily cohesive, high-performing team of engineers and scientists that have consistently delivered world class, state-of -the-art products. In just 14 weeks her team delivered innovative large several 125 lpm Chromatography systems combined with buffer blending capabilities that enabled a client to scale up Covid vaccine scale from 40M doses/mo to 200M doses/mo during the height of the pandemic! Ms. Chabra’s has a B.S. from California State University at San Francisco. She is an inventor as well and has authored several patents.
Salah Ahmed
Director of Quality & Tech Support
Mr. Ahmed is currently Director of Quality and Technical Support at Sepragen. He over 30 years of experience in product development, manufacturing and technical support at Beatrice Foods, Dairy Research Inc and several others food and nutritional companies. Mr Ahmed thus brings with him a command of all aspects of process operations and equipment included in fermentation, separation and purification on a very large scale. Mr. Ahmed has a M.S. in Food Science from the University of Illinois.
Board of Directors
Vinit Saxena
Mr. Saxena is the Founder and Chief Executive Officer. His background includes over 25 years of senior management experience in marketing operations at biotech companies and suppliers such as Bio-Rad Laboratories and Bio-Response (now Baxter Healthcare). Mr. Saxena started the Process Chromatography business for Bio-Rad and is credited with setting up one of the first large scale antibody production facilities in the world. Mr. Saxena has an M.S. in Chemical Engineering from Syracuse University and an M.B.A. from the University of California, Berkeley. He holds 6 patents.
Henry Edmunds
Dr. Edmunds is currently acting as Chief Financial Officer of Sepragen. He also serves as President of Biopheresis. Previously, he served as Vice President and Chief Financial Officer of Prometheus, a pharmaceutical company. He also served as Vice President of Corporate Development and Chief Financial Officer of SangStat Medical Corporation, and as Director of Business development at Genencor, Inc. Dr. Edmunds received his Ph.D. in Biotechnology from the University of California, Berkeley and his M.B.A. from the Stanford School of Business.
Renu Chabra
Renu Chabra, Vice President of Manufacturing and Engineering at Sepragen, Ms. Chabra has over 25 years of professional experience at start-up companies such as Kinetech and Transtech, and global companies such as Varian and Intergraph. Her experience includes technical management in product development, engineering, software development, manufacturing and operations including off shoring. Over the last ten years, Ms. Chabra has been responsible for the development of Sepragen’s QuantaSep chromatography workstations while directing Sepragen’s manufacturing activities. Ms. Chabra holds a B.S. from California State University, San Francisco.
George Martinez
Advisor
Mr Martinez is an accomplished and talented entrepreneur and visionary. Mr. Martinez is the founder and CEO of Allegiance Bank. Prior to founding Allegiance he was the co-founder, Chairman and CEO of Sterling Bancshares and was responsible for building the bank to over $3 Bn in assets. George currently serves on various boards and charities and mentors companies and entrepreneurs in performance-based leadership
Capabilities Brochure

Please wait while flipbook is loading. For more related info, FAQs and issues please refer to DearFlip WordPress Flipbook Plugin Help documentation.

Sepragen, the original inventors of radial flow chromatography, is dedicated to supplying powerful, innovative tools and technologies which enable our customers to develop and manufacture life-saving biological drugs, vaccines and diagnostics quickly and cost-effectively.

©2025 - Sepragen Corporation - All right reserved

Contacts